SCIENCE

COMPELLING DATA AND CLEAR MILESTONES

We have generated substantial pre-clinical data supporting the potential of our approach to protect peripheral nerves while maintaining chemotherapy exposure. Paired with extensive safety data and early human proof of concept case series, we are advancing rapidly toward key milestones.

MITOCHONDRIAL DYSFUNCTION IS CENTRAL TO CIPN FOR MANY CHEMO AGENTS

Neurotoxic chemotherapeutic agents target multiple aspects of the sensory peripheral nerve.

1.Ann Neurol. 2017 Jun 5;81(6):772–781.

2.Soejitno, A., Widyadharma, I.P.E. Chemotherapy-induced peripheral neuropathy biomarkers: current updates, challenges, and potentials. Egypt J Neurol Psychiatry Neurosurg 60, 92 (2024).

CFB-001 PRESERVES MITOCHONDRIAL STRUCTURE IN HUMAN CELLS UNDER OXIDATIVE STRESS

TEM images show HQ (hydroquinone) caused substantial disruption of mitochondrial morphology
CFB-001 significantly protected mitochondria from HQ-induced oxidative stress

1. Data on file.

CFB-001 DOESN’T AFFECT CISPLATIN OR CANCER CELLS IN MULTIPLE CANCER CELL LINES

Protects nerves without protecting tumors: no effect on cancer cell growth or on cisplatin’s potency

Method: cancer cells (10,000/well) grown for 24 h, then treated with serial concentrations of cisplatin (triplicate wells) with or without 100 or 400 µM CFB-001 for 72 h; viable cells measured by MTT assay. Data from Melior Discovery, Exton, PA.

CFB-001 DOESN’T AFFECT CANCER METASTASES IN A MOUSE MODEL

In an aggressive metastatic melanoma model, CFB-001 did not change lung tumor burden or body weight

B16F10: highly metastatic mouse melanoma model. Lung index used as a measure of metastatic tumor burden. Data from Melior Discovery, Exton, PA.

ANIMAL MODEL: CFB-001 SIGNIFICANTLY REDUCED CIPN THROUGH TWO ROUNDS OF CISPLATIN

Topical CFB-001 protected mice from cisplatin-induced pain sensitivity during both chemotherapy cycles

von Frey test: higher withdrawal force = less pain sensitivity. Student’s t-test vs. vehicle. Data from MD Biosciences, Cambridge, MA.

Report abuse